人二倍体细胞狂犬病疫苗可引发针对欧洲和澳大利亚蝙蝠狂犬病病毒的交叉中和及交叉保护免疫反应。

Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses.

作者信息

Brookes S M, Parsons G, Johnson N, McElhinney L M, Fooks A R

机构信息

Rabies Research and Diagnostic Group, Virology Department, [World Health Organisation Collaborating Centre]Veterinary Laboratories Agency (Weybridge), New Haw, Addlestone, Surrey, UK.

出版信息

Vaccine. 2005 Jul 14;23(32):4101-9. doi: 10.1016/j.vaccine.2005.03.037.

DOI:10.1016/j.vaccine.2005.03.037

PMID:15964478

Abstract

The ability of antibodies elicited against the rabies human diploid cell vaccine (HDCV) to neutralise European bat Lyssaviruses (EBLV types-1 and -2), Australian bat Lyssavirus and classical rabies virus (RABV) has been evaluated using modified fluorescent antibody virus neutralisation (mFAVN) assays. Ninety-six percent (48 of 50) of the human post-vaccinated sera tested cross-neutralised these viruses (>or=0.5 IU/ml). Cross-protection experiments using inbred mice (RIII, k/k haplotype) were also assessed. Mice were given HDCV (twice by the intra-peritoneal route) and challenged (intra-cranially or peripherally) with a lethal dose (25 MLD(50)) of the individual viruses. The vaccine conferred statistically significant protection in 80--100% of animals challenged via the peripheral route. Levels of protection were lower following intra-cranial (i.c.) challenge. Our data provides strong evidence for broad spectrum cross-neutralisation and cross-protection of phylogroup I lyssaviruses using rabies HDCV.

摘要

已使用改良荧光抗体病毒中和（mFAVN）试验评估了针对狂犬病人类二倍体细胞疫苗（HDCV）产生的抗体中和欧洲蝙蝠狂犬病病毒（EBLV - 1型和 - 2型）、澳大利亚蝙蝠狂犬病病毒和经典狂犬病病毒（RABV）的能力。96%（50份中有48份）接种疫苗后的人血清对这些病毒具有交叉中和作用（≥0.5 IU/ml）。还评估了使用近交系小鼠（RIII，k/k单倍型）进行的交叉保护实验。给小鼠腹腔注射HDCV（两次），然后用致死剂量（25 MLD(50)）的各病毒进行颅内或外周攻击。该疫苗对80 - 100%经外周途径攻击的动物提供了具有统计学意义的保护。颅内攻击后的保护水平较低。我们的数据为使用狂犬病HDCV对I类狂犬病病毒进行广谱交叉中和和交叉保护提供了有力证据。